sars-cov-2 mrna vaccine, bivalent
VaccineexperimentalCOVID-19
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 26, 2022 (NCT05547243)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
immunity, active - Sars-COV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06831786 | Early Phase 1 (Phase 1) | Mar 1, 2024 | Prince of Songkla University |
| NCT05939648 | Phase 2 | Oct 9, 2023 | AIM Therapeutics Inc., Government of China |
| NCT05939596 | Phase 1 | Aug 10, 2023 | Bengbu Medical College, Government of China |
| NCT05547243 | N/A | Sep 26, 2022 | AIM Therapeutics Inc., Bengbu Medical College, Government of China |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 3 | 2022 |
| AIM Therapeutics Inc. | For profit | 2 | 0 | 2 | 2022 |
| Bengbu Medical College | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Prince of Songkla University | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1